Key result
Intravenous thrombolysis resulted in significantly greater neurological improvement (higher delta NIHSS) compared to antiplatelet therapy in stroke patients aged 75 years and older.
Why the study?
Concerns about complications often reduce the use of intravenous thrombolysis and mechanical thrombectomy in older acute ischaemic stroke patients, who are preferentially managed with antiplatelet therapy.
Do reperfusion treatments (IT, MT, or IT+MT) improve clinical outcomes and safety compared to antiplatelet therapy in acute ischaemic stroke patients aged over 75 years?
Observational (n=273)
Yes
Do reperfusion treatments (IT, MT, or IT+MT) improve clinical outcomes and safety compared to antiplatelet therapy in acute ischaemic stroke patients aged over 75 years?
In older patients (≥75 years) with acute ischaemic stroke, intravenous thrombolysis provides better neurological improvement than antiplatelet therapy with a relatively safe profile, whereas mechanical thrombectomy is associated with higher rates of haemorrhagic infarction.
Answers are grounded in this paper and cite their sources.
Supports hypothesis generation on reperfusion vs antiplatelet strategies in oldest-old stroke; leaves optimal selection open pending prospective data.
INTRODUCTION: Intravenous thrombolysis (IT) and mechanical thrombectomy (MT) have significantly changed the clinical outcome of acute ischaemic stroke (AIS). Concerns about possible complications often reduce the use of these treatment options for older patients, preferentially managed with antiplatelet therapy (AT). Aim of this study was to evaluate, in a population of middle-old (75-84 years) and oldest-old (≥ 85 years) subjects, the efficacy and safety of different treatments for AIS (IT, IT + MT, MT or AT), mortality and incidence of serious complications. PATIENTS AND METHODS: All patients aged over 75 years admitted for AIS in two Stroke Units were enrolled. The physician in each case considered all treatment options and chose the best approach. NIHSS and modified Rankin Scale (mRS) were obtained and differences between admission and discharge scores, defined as delta(NIHSS) and delta(mRS), were calculated. The relationship between delta(NIHSS), delta(mRS) and type of procedure was analysed with a GLM/Multivariate model. Differences in mortality and incidence of serious complications were analysed with the chi-square test. RESULTS: A total of 273 patients, mean age 84.07 (± 5.47) years, were included. The Delta(NIHSS) was significantly lower in patients treated with AT than in those treated with IT and MT (p < 0.009 and p < 0.005, respectively). Haemorrhagic infarction occurrence was significantly lower (p < 0.0001) among patients treated with AT (10.6%) or IT (16.7%) compared to MT (34.9%) or MT + IT (37.0%). No significant difference was observed for in-hospital mortality. Age did not influence the outcome. CONCLUSIONS: Our results suggest that IT and AT are effective and relatively safe approaches in middle-aged and older patients.
No takes yet. Share an insight, caveat, or question.
Viticchi et al. (2022) conducted an observational in Acute ischaemic stroke (n=273). Intravenous thrombolysis (IT) vs. Antiplatelet therapy (AT) was evaluated on Delta(NIHSS) (difference between admission and discharge NIHSS) (MD 2.75, 95% CI 1.13-4.37, p=0.009). Intravenous thrombolysis resulted in significantly greater neurological improvement (higher delta NIHSS) compared to antiplatelet therapy in stroke patients aged 75 years and older.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: